Capricor Therapeutics Inc (NAS:CAPR) Stock News, Headlines & Updates
Capricor Therapeutics Inc Stock News from GuruFocus
- 1
Jul 01, 2024
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
Marketwired • 8:00am
Jun 28, 2024
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Marketwired • 8:00am
Jun 25, 2024
CORRECTION: Capricor Therapeutics
Marketwired • 10:00am
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Marketwired • 8:00am
Jun 11, 2024
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Marketwired • 9:00am
Jun 04, 2024
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Marketwired • 8:00am
May 14, 2024
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Financial Insights
GuruFocus Research • 1:04am
Q1 2024 Capricor Therapeutics Inc Earnings Call Transcript
GuruFocus Research • 11:03pm
May 13, 2024
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Marketwired • 4:00pm
May 09, 2024
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Marketwired • 9:00am
May 08, 2024
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
Marketwired • 8:00am
May 06, 2024
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Marketwired • 8:00am
Apr 24, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news